In the past decades, when dacarbazine-based chemotherapy was the treatment of choice, the median survival of patients with unresectable melanoma was only six to nine months and only 10–15% of the p...
No takes yet. Share an insight, caveat, or question.
Mattila et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: